These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11358679)

  • 21. Incipient and overt diabetic nephropathy in African Americans with NIDDM.
    Dasmahapatra A; Bale A; Raghuwanshi MP; Reddi A; Byrne W; Suarez S; Nash F; Varagiannis E; Skurnick JH
    Diabetes Care; 1994 Apr; 17(4):297-304. PubMed ID: 8026285
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM.
    Penno G; Chaturvedi N; Talmud PJ; Cotroneo P; Manto A; Nannipieri M; Luong LA; Fuller JH
    Diabetes; 1998 Sep; 47(9):1507-11. PubMed ID: 9726242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group.
    Lancet; 1997 Jun; 349(9068):1787-92. PubMed ID: 9269212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment.
    Derosa G; D'Angelo A; Franzetti IG; Ragonesi PD; Gadaleta G; Scalise F; Ciccarelli L; Piccinni MN; Cicero AF
    J Clin Pharm Ther; 2009 Jun; 34(3):267-76. PubMed ID: 19650249
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
    Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
    Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT).
    Teo KK; Burton JR; Buller CE; Plante S; Catellier D; Tymchak W; Dzavik V; Taylor D; Yokoyama S; Montague TJ
    Circulation; 2000 Oct; 102(15):1748-54. PubMed ID: 11023927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of 3 years of antihypertensive therapy on renal structure in type 1 diabetic patients with albuminuria: the European Study for the Prevention of Renal Disease in Type 1 Diabetes (ESPRIT).
    Diabetes; 2001 Apr; 50(4):843-50. PubMed ID: 11289051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment.
    Tonolo G; Ciccarese M; Brizzi P; Puddu L; Secchi G; Calvia P; Atzeni MM; Melis MG; Maioli M
    Diabetes Care; 1997 Dec; 20(12):1891-5. PubMed ID: 9405913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions.
    Collins R; Armitage J; Parish S; Sleight P; Peto R;
    Lancet; 2004 Mar; 363(9411):757-67. PubMed ID: 15016485
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating plasma vascular endothelial growth factor and microvascular complications of type 1 diabetes mellitus: the influence of ACE inhibition.
    Chaturvedi N; Fuller JH; Pokras F; Rottiers R; Papazoglou N; Aiello LP;
    Diabet Med; 2001 Apr; 18(4):288-94. PubMed ID: 11437859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.
    Olsson AG; Eriksson M; Johnson O; Kjellström T; Lanke J; Larsen ML; Pedersen T; Tikkanen MJ; Wiklund O;
    Clin Ther; 2003 Jan; 25(1):119-38. PubMed ID: 12637115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2 Diabetic Nephropathy (ACTION II).
    Freedman BI; Wuerth JP; Cartwright K; Bain RP; Dippe S; Hershon K; Mooradian AD; Spinowitz BS
    Control Clin Trials; 1999 Oct; 20(5):493-510. PubMed ID: 10503809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipoprotein (a) and microvascular disease in type 1 (insulin-dependent) diabetes.
    Winocour PH; Bhatnagar D; Ishola M; Arrol S; Durrington PN
    Diabet Med; 1991 Dec; 8(10):922-7. PubMed ID: 1838043
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group.
    Kidney Int; 1995 Jun; 47(6):1703-20. PubMed ID: 7643540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients.
    Tonolo G; Melis MG; Formato M; Angius MF; Carboni A; Brizzi P; Ciccarese M; Cherchi GM; Maioli M
    Eur J Clin Invest; 2000 Nov; 30(11):980-7. PubMed ID: 11114960
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Significance of arterial blood pressure for the development of microalbuminuria and retinopathy in type I diabetes mellitus].
    Watschinger B; Schnack C; Bruck S; Stelzer N; Gisinger C; Schernthaner G
    Klin Wochenschr; 1988 Nov; 66(21):1074-8. PubMed ID: 3236757
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Occurrence and interrelationships of complications in insulin-dependent diabetes in Finland.
    Ebeling P; Koivisto VA
    Acta Diabetol; 1997 Mar; 34(1):33-8. PubMed ID: 9134055
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.
    Estacio RO; Jeffers BW; Gifford N; Schrier RW
    Diabetes Care; 2000 Apr; 23 Suppl 2():B54-64. PubMed ID: 10860192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients.
    Gaudiani LM; Lewin A; Meneghini L; Perevozskaya I; Plotkin D; Mitchel Y; Shah S
    Diabetes Obes Metab; 2005 Jan; 7(1):88-97. PubMed ID: 15642080
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
    Rosen JB; Jimenez JG; Pirags V; Vides H; Hanson ME; Massaad R; McPeters G; Brudi P; Triscari J
    Diab Vasc Dis Res; 2013 May; 10(3):277-86. PubMed ID: 23288881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.